Finance

Lists
ABBV:NYSE
AbbVie Common Stock
US$ २६२.८२
+१.११%
(+२.८९) 1D
US$ २६२.८२
०.००% (०.००)
After hours
Closed: अक्टोबर २, १६:०२:३३ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABBV...
Open
US$ २५९.७४
High
US$ २६४.०६
Low
US$ २५७.८७
Mkt. cap
४.६४ खरब
Avg. vol.
४१.४१ लाख
Volume
५८.६३ लाख
Dividend
२.६३%
Quarterly dividend
US$ १.७३
Ex-dividend date
२०२६ अक्टोबर १५
P/E ratio
७४.३३
52-wk high
US$ २६९.३९
52-wk low
US$ १९०.७५
EPS
US$ ३.५४
Beta
०.२३
Shares outstanding
१.७७ अरब
No. of employees
५७ हजार
Open
US$ २५९.७४
High
US$ २६४.०६
Low
US$ २५७.८७
Mkt. cap
४.६४ खरब
Avg. vol.
४१.४१ लाख
Volume
५८.६३ लाख
Dividend
२.६३%
Quarterly dividend
US$ १.७३
Ex-dividend date
२०२६ अक्टोबर १५
P/E ratio
७४.३३
52-wk high
US$ २६९.३९
52-wk low
US$ १९०.७५
EPS
US$ ३.५४
Beta
०.२३
Shares outstanding
१.७७ अरब
No. of employees
५७ हजार
News stories
From web sources and news partners
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About AbbVie Common Stock
CEORobert A. Michael
Employees५७ हजार
Founded२०१२ अप्रिल १०
HeadquartersNorth Chicago, इलिनोइ, संयुक्त राज्य अमेरिका
Sector-
Websiteabbvie.com
Analyst ratings
Based on 23 analysts giving stock ratings to ABBV in the past 3 months
Strong buy
Buy
19
Hold
4
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for ABBV in the last 3 months.
Highest
Current US$ २६२.८२
US$ ३१५.०० (+१९.८५%)
Average
US$ २८१.६७ (+७.१७%)
Lowest
US$ २२५.०० (-१४.३९%)
Analyst
Recommendation
Action
Price target
Projected
Date
Louise Chen
Scotiabank
Buy
Maintained
US$ २८०.००
+६.५%
10/01/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
US$ २९०.००
+१०.३%
09/28/2026
Evan Seigerman
BMO Capital
Buy
Reiterated
US$ ३००.००
+१४.१%
09/29/2026
Geoff Meacham
Citi
Hold
Maintained
US$ २६०.००
-१.१%
09/29/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
US$ २८९.००
+१०%
10/01/2026
Tim Anderson
Bank of America Securities
Buy
Reiterated
US$ २८९.००
+१०%
09/29/2026
Trung Huynh
RBC Capital
Buy
Maintained
US$ २८०.००
+६.५%
09/29/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/28/2026
Steve Scala
TD Cowen
Buy
Maintained
US$ २८०.००
+६.५%
09/28/2026
Chris Schott
J.P. Morgan
Buy
Maintained
US$ २८५.००
+८.४%
09/25/2026
David Amsellem
Piper Sandler
Buy
Reiterated
US$ ३०३.००
+१५.३%
09/23/2026
Luisa Hector
Berenberg Bank
Buy
Reiterated
US$ २७५.००
+४.६%
09/10/2026
Rajesh Kumar
HSBC
Buy
Maintained
US$ ३१५.००
+१९.९%
09/10/2026
William Katz
TD Cowen
Buy
Reiterated
US$ २८०.००
+६.५%
09/04/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
US$ ३००.००
+१४.१%
08/17/2026
Alexandria Hammond
Wolfe Research
Buy
Upgraded
US$ ३००.००
+१४.१%
08/13/2026
Emily Field
Barclays
Buy
Reiterated
US$ ३००.००
+१४.१%
08/11/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Reiterated
US$ २६०.००
-१.१%
08/10/2026
Hans Engel
Erste Group
Buy
Upgraded
-
-
08/05/2026
Vamil Divan
Guggenheim
Buy
Reiterated
US$ २८८.००
+९.६%
08/03/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
US$ २९६.००
+१२.६%
08/03/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
US$ २८५.००
+८.४%
07/31/2026
Courtney Breen
Bernstein
Hold
Maintained
US$ २२५.००
-१४.४%
07/22/2026
Asad Haider
Goldman Sachs
Hold
Maintained
US$ २४४.००
-७.२%
07/21/2026
Michael Yee
UBS
Hold
Reiterated
US$ २६०.००
-१.१%
07/13/2026
Michael Harvey
RBC Capital
Buy
Reiterated
US$ २८०.००
+६.५%
07/10/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
US$ २८०.००
+६.५%
06/23/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
US$ २८०.००
+६.५%
06/23/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
US$ २५०.००
-४.९%
05/13/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
US$ २६२.००
-०.३%
04/20/2026
Nico Chen
DBS
Hold
Maintained
US$ २३०.००
-१२.५%
02/25/2026
Last report
२०२६ जुलाई ३१
Fiscal period
Q2 2026
EPS / Est. (USD)
US$ ३.६५ / US$ ३.६१
+१.०८%beat
Revenue / Est. (USD)
१६.९९ अरब / १६.७६ अरब
+१.३६%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१५.७८ अरब
१६.६२ अरब
१५.०० अरब
१६.९९ अरब
Cost of goods sold
४.४६ अरब
४.५५ अरब
४.२२ अरब
४.२९ अरब
Cost of revenue
४.४६ अरब
४.५५ अरब
४.२२ अरब
४.२९ अरब
Research and development expenses
२.२९ अरब
२.५८ अरब
२.४७ अरब
२.३४ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३.४३ अरब
३.८२ अरब
३.४९ अरब
३.५५ अरब
Operating expense
५.७२ अरब
६.४० अरब
५.९६ अरब
५.९० अरब
Total operating expenses
१०.१८ अरब
१०.९५ अरब
१०.१८ अरब
१०.१९ अरब
Operating income
५.६० अरब
५.६७ अरब
४.८२ अरब
६.८० अरब
Other non operating income
१९.९० करोड
१२.०० करोड
-३०.०० लाख
-५.५० करोड
EBT including unusual items
७१.४० करोड
२.६७ अरब
१.०४ अरब
४.२८ अरब
EBT excluding unusual items
५.११ अरब
५.१२ अरब
४.१९ अरब
६.०७ अरब
Income tax expense
५२.६० करोड
८५.३० करोड
३४.२० करोड
६६.२० करोड
Effective tax rate
७३.६७%
३१.९७%
३२.९२%
१५.४७%
Other operating expenses
-
-
-
-
Net income
१८.६० करोड
१.८२ अरब
६९.५० करोड
३.६१ अरब
Net profit margin
१.१८%
१०.९३%
४.६३%
२१.२७%
Earnings per share
१.८६
२.७१
२.६५
३.६५
Interest and investment income
७.२० करोड
५.९० करोड
७.२० करोड
६.७० करोड
Interest expense
-७३.९० करोड
-७१.४० करोड
-७१.७० करोड
-७४.६० करोड
Net interest expenses
-६६.७० करोड
-६५.५० करोड
-६४.५० करोड
-६७.९० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
७.६६ अरब
७.६६ अरब
६.७६ अरब
८.६८ अरब
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू